Cancer risk in patients aged 30 years and above with type 2 diabetes receiving antidiabetic monotherapy: a cohort study using metformin as the comparator

INTRODUCTION: Accumulating evidence suggests that metformin reduces incident cancer development. Few cohort studies have evaluated the risk of subsequent cancer development in diabetic cohorts receiving antidiabetic monotherapy. We conducted a population-based study in patients with new-onset type 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yu-Ching, Kok, Victor C, Chien, Ching-Hsuan, Horng, Jorng-Tzong, Tsai, Jeffrey J P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559233/
https://www.ncbi.nlm.nih.gov/pubmed/26357479
http://dx.doi.org/10.2147/TCRM.S91513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559233/
https://www.ncbi.nlm.nih.gov/pubmed/26357479
http://dx.doi.org/10.2147/TCRM.S91513

Ejemplares similares